Today

Agents

Chat

Arena

Discover

More

App

Nasus Pharma wins FDA clearance to start NS002 anaphylaxis study - NSRX News | Rallies

Nasus Pharma wins FDA clearance to start NS002 anaphylaxis study

NSRX•2026-09-14

Pivotal study and data timeline

Pivotal study targeted for Q4 2026; topline data expected in Q1 2027.

FDA clears IND for NS002 anaphylaxis study

FDA cleared the IND for Nasus Pharma’s NS002 intranasal epinephrine powder, enabling a clinical study in anaphylaxis.

Related News

Janux doses first patient in Phase 1 trial of JANX013 in metastatic prostate cancer

JANX•2026-09-14

Leonardo DRS wins USD 39.6 million Navy contract for EA-18G communications upgrades

DRS•2026-09-14

NewtekOne declares quarterly cash dividend of $0.19 a share on common stock

NEWT

•

2026-09-14

Enbridge closes CDN$ 3 billion common share offering, issues 44,735,000 shares

ENB•2026-09-14

Highwoods Properties declares R$ 0.87 per unit dividend for Q3 2026, payable Sept. 15

HIW•2026-09-14